HIV therapy, metabolic syndrome, and cardiovascular risk

Current Atherosclerosis Reports

Volumn 10, Issue 1, 2008, Pages 61-70

  Pao, Vivian ^b   Lee, Grace A ^b   Grunfeld, Carl ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TIPRANAVIR; ZIDOVUDINE;

ATHEROSCLEROSIS; BLOOD PRESSURE; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EXPOSURE; DRUG MECHANISM; HEALTH STATUS; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOATROPHY; METABOLIC DISORDER; OBESITY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; WAIST CIRCUMFERENCE;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COMORBIDITY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; INDINAVIR; METABOLIC SYNDROME X; PREVALENCE; RISK FACTORS; RITONAVIR; TERMINOLOGY AS TOPIC;

EID: 40749154715     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0010-6     Document Type: Review

References (55)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Lee GA, Rao MN, Grunfeld C: The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep 2005, 2:39-50.
3. Safrin S, Grunfeld C: Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13:2493-2505.
4. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
5. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, Switzerland: World Health Organization; 1999.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
7. Grundy SM, Brewer HB Jr, Cleeman JI, et al.: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
8. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetes Med 2006, 23:469-480.
9. Balkau B, Charles MA, Drivsholm T, et al.: Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002, 28:364-376.
10. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
11. Bergersen BM, Schumacher A, Sandvik L, et al.: Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis 2006, 38:682-689.
12. Bernal E, Masia M, Padilla S, et al.: Prevalence and characteristics of metabolic syndrome among HIV-infected patients from a Mediterranean cohort [Spanish]. Med Clin (Barc) 2007, 128:172-175.
13. Bonfanti P, Giannattasio C, Ricci E, et al.: HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007, 45:426-431.
14. Bonfanti P, Ricci E, de Socio G, et al.: Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study. J Acquir Immune Defic Syndr 2006, 42:128-131.
15. Bruno R, Gazzaruso C, Sacchi P, et al.: High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr 2002, 31:363-365.
16. Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL, et al.: Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 2006, 55:940-945.
17. Gazzaruso C, Bruno R, Garzaniti A, et al.: Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003, 21:1377-1382.
18. Gazzaruso C, Sacchi P, Garzaniti A, et al.: Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002, 25:1253-1254.
19. Jacobson DL, Tang AM, Spiegelman D, et al.: Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006, 43:458-466.
20. Jerico C, Knobel H, Montero M, et al.: Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005, 28:132-137.
21. Mondy K, Overton ET, Grubb J, et al.: Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007, 44:726-734.
22. Samaras K, Wand H, Law M, et al.: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007, 30:113-119.
23. Carr A, Samaras K, Thorisdottir A, et al.: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
24. Grunfeld C, Pang M, Doerrler W, et al.: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
25. El-Sadr WM, Mullin CM, Carr A, et al.: Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005, 6:114-121.
26. Lee GA, Seneviratne T, Noor MA, et al.: The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004, 18:641-649.
27. Noor MA, Lo JC, Mulligan K, et al.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15: F11-F18.
28. Noor MA, Parker RA, O'Mara E, et al.: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004, 18:2137-2144.
29. Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal patients. AIDS 2000, 14:51-57.
30. van der Valk M, Kastelein JJ, Murphy RL, et al.: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001, 15:2407-2414.
31. Riddle TM, Schildmeyer NM, Phan C, et al.: The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res 2002, 43:1458-1463.
32. van Leth F, Phanuphak P, Stroes E, et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004, 1:e19.
33. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191-201.
34. Fontas E, van Leth F, Sabin CA, et al.: Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004, 189:1056-1074.
35. Noor MA, Seneviratne T, Aweeka FT, et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1-8.
36. Lee GA, Rao MN, Mulligan K, et al.: The Effects of ritonavir and amprenavir on insulin-mediated glucose disposal in healthy volunteers: two randomized, placebo-controlled, cross-over trials. AIDS 2007, In press.
37. Lee GA, Lo JC, Aweeka F, et al.: Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006, 43:658-660.
38. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by hiv protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
39. Brown TT, Li X, Cole SR, et al.: Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005, 19:1375-1383.
40. Schwarz JM, Lee GA, Park S, et al.: Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004, 18:1852-1854.
41. Noor MA, Flint OP, Maa JF, Parker RA: Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006, 20:1813-1821.
42. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121-131.
43. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006, 42:562-571.
44. Grunfeld C, Rimland D, Gibert CL, et al.: Association of upper trunk and visceral adipose tissue. J Acquir Immune Defic Syndr 2007 [Epub ahead of print].
45. Bergersen BM, Sandvik L, Dunlop O, et al.: Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003, 22:731-736.
46. Palacios R, Santos J, Garcia A, et al.: Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med 2006, 7:10-15.
47. Seaberg EC, Munoz A, Lu M, et al.: Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005, 19:953-960.
48. Thiebaut R, El-Sadr WM, Friis-Moller N, et al.: Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005, 10:811-823.
49. Feingold K, Krauss R, Pang M, et al.: The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993, 76:1423-1427.
50. Khovidhunkit W, Kim MS, Memon RA, et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196.
51. Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.
52. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002, 30:471-477.
53. Friis-Moller N, Sabin CA, Weber R, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
54. Friis-Moller N, Reiss P, Sabin CA, et al.: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735.
55. Coplan PM, Nikas A, Japour A, et al.: Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003, 19:449-455.